Kidney Disease/Hypertension in African Americans-DCC

非裔美国人的肾脏疾病/高血压-DCC

• 批准号: 7495634
• 负责人: JENNIFER J GASSMAN
• 金额: $ 38万
• 依托单位: CLEVELAND CLINIC LERNER COM-CWRU
• 依托单位国家: 美国
• 财政年份: 1994
• 资助国家: 美国
• 起止时间: 1994-08-15 至 2010-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7495634
• 关键词: Address; African American; American; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biological; Blood Pressure; Cardiovascular Diseases; Cardiovascular system; Caring; Cessation of life; Chronic Kidney Insufficiency; Clinical; Cohort Studies; Collection; Communities; Creatinine; Data; Data Analyses; Data Collection; Data Coordinating Center; Data Quality; Databases; Development; Disease Progression; Economic Factors; Economics; End Point; End stage renal failure; Enrollment; Genetic; Hypertension; Incidence; Individual; Intervention Trial; Kidney; Kidney Diseases; Kidney Failure; Laboratories; Lead; Long-Term Effects; Manuals; Measurement; Metabolic; Metoprolol; Monitor; Morbidity - disease rate; Nephrosclerosis; Observational Study; Operative Surgical Procedures; Outcome; Participant; Patients; Pattern; Pharmaceutical Preparations; Physiological; Population; Process; Proteinuria; Protocols documentation; Publications; Publishing; Ramipril; Randomized; Randomized Controlled Clinical Trials; Renal function; Reporting; Research; Research Personnel; Risk; Risk Factors; Serum; Specimen; System; Testing; Work; blood pressure regulation; cohort; follow-up; hypertension treatment; mortality; prevent; prospective

Hypertensive kidney disease commonly progresses. The primary objective of the AASK (African American Study of Kidney Disease and Hypertension) Cohort Study is to determine prospectively the course of kidney function and risk factors for kidney disease progression in African-Americans with hypertensive kidney disease who receive recommended antihypertensive therapy. A secondary objective is to determine the occurrence of cardiovascular disease and assess its risk factors. The AASK Cohort Study is a prospective, observational study that is an extension of the AASK trial. The AASK trial tested the effects of 3 medications used as initial antihypertensive therapy (ramipril, metoprolol and amlodipine) and 2 levels of blood pressure control. Of the 1,094 trial participants, approximately 650 to 700 individuals who have not reached end stage renal disease (ESRD) will likely enroll in the Cohort Study. Risk factors to be studied include environmental, genetic, physiologic, and socio-economic variables. The primary renal outcome is a composite clinical outcome defined by doubling of serum creatinine, ESRD, or death. Medication treatment for hypertension, beginning with the angiotensin converting enzyme inhibitor ramipril, is offered to all participants. In this fashion, the study directly controls two of the major determinants of kidney disease progression (treatment of hypertension and use of reno-protective, antihypertensive medication). The minimum duration of follow-up in the Cohort Study is 5 years (total of 9 to 12 years, including the period of the AASK trial). Ultimately, data from the AASK Cohort Study should enhance our understanding of the risk factors and processes that determine the progression of kidney disease. Such results might eventually lead to new strategies that delay or prevent ESRD.

高血压肾脏疾病通常会进展。 AASK的主要目标（非裔美国人 肾脏疾病和高血压的研究）研究是确定肾脏的过程 高血压肾脏的非裔美国人的肾脏疾病进展的功能和危险因素 接受建议的降压治疗的疾病。次要目标是确定 心血管疾病的发生并评估其危险因素。 AASK队列研究是一项前瞻性，观察性研究，是AASK试验的扩展。这 AASK试验测试了3种用作初始降压治疗（Ramipril，Metoprolol）的作用 和氨氯地平）和2个水平的血压控制水平。在1,094名试验参与者中，约为650 700名尚未达到末期肾脏疾病（ESRD）的人可能会参加队列研究。 要研究的危险因素包括环境，遗传，生理和社会经济变量。这 主要肾脏结果是由血清肌酐，ESRD或 死亡。从血管紧张素转化酶抑制剂开始 拉米普里（Ramipril）提供给所有参与者。以这种方式，研究直接控制了两个主要决定因素 肾脏疾病进展（高血压治疗和肾脏保护性，降压药的使用 药物）。队列研究中的最小随访持续时间为5年（总计9至12年， 包括AASK试验期间）。 最终，来自AASK队列研究的数据应增强我们对风险因素和的理解 决定肾脏疾病进展的过程。这样的结果最终可能导致新 延迟或阻止ESRD的策略。